Linus Health Presents New Data on AI-Based Cognitive Assessment Tools at CTAD 2025

Five scientific posters examine early detection methods, digital cognitive assessments, and clinical trial readiness in Alzheimer’s research

Linus Health announced that it will present new real-world evidence on its AI-enabled cognitive assessment tools at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, held December 1–4 in San Diego. The company’s research examines how digital assessments may support early detection of Alzheimer’s disease and improve clinical trial processes.

At the conference, Linus Health will share findings across five scientific posters. The work focuses on the company’s electronic Person-Specific Outcome Measure (ePSOM), Digital Clock and Recall (DCR), and Digital Assessment of Cognition (DAC) tools.

According to the company, the research indicates that these tools may identify early cognitive changes, support selection of individuals eligible for Alzheimer’s disease–modifying treatments, provide patient-defined outcome measures, and enable remote screening methods. The studies include evaluations of accuracy, feasibility, and correlations with biomarker status.

All five posters will be presented on December 4 as part of CTAD sessions focused on cognitive and functional endpoints and cognitive assessment in clinical trials.

Titles and primary focuses of the poster presentations include:

• P313: An assessment of ePSOM’s feasibility, applicability, and acceptability in Japanese memory clinics.
• P315: An analysis of self-reported cognitive priorities and their relationship to cognitive impairment status.
• P340: Data on the DCR tool’s ability to identify individuals likely to be amyloid-positive and eligible for treatment.
• P343: Evaluation of the DAC tool’s prediction of p-tau217 blood biomarker status through a remote assessment.
• P306: Examination of ePSOM data linking cognitive performance and quality-of-life measures to personal priorities.

Linus Health also announced the acceptance of a manuscript titled Concurrent detection of cognitive impairment and amyloid positivity with a multimodal machine learning-enabled digital cognitive assessment. The study will appear in Alzheimer’s Research & Therapy and reports that the tablet-based DCR assessment detected cognitive impairment and estimated amyloid positivity within a three-minute evaluation.

During the CTAD conference, Linus Health representatives plan to meet with partners in the life sciences sector to discuss potential uses of the company’s digital tools in trial recruitment, outcome measurement, and real-world evidence generation. A virtual booth will also be available to conference participants.

Linus Health is a Boston-based company that develops digital tools aimed at supporting detection and assessment of cognitive and brain health concerns. Its work integrates neuroscience, clinical input, and AI-based analysis. The company collaborates with healthcare organizations, research institutions, and industry partners on projects involving early detection and intervention strategies.

More information about Linus Health is available on the company’s website and LinkedIn page.